Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Sci Rep ; 11(1): 8493, 2021 04 19.
Artigo em Inglês | MEDLINE | ID: mdl-33875750

RESUMO

Renal angiomyolipomas hemorrhage is associated with their size and vascular constitution. The effects of sirolimus on different components of angiomyolipomas was analyzed in patients with tuberous sclerosis complex, sporadic lymphangioleiomyomatosis and multiple sporadic angiomyolipomas. Thirty angiomyolipomas from 14 patients treated with sirolimus were retrospectively evaluated. A Hounsfield-unit threshold was used to classify angiomyolipomas in fat-rich, fat-poor and intermediate-fat tumors, and to categorize tumor compartments in fat rich, fat poor, intermediate fat and highly vascularized. Diameter variations were measured to assess the effects on aneurysmatic/ectatic vascular formations. Volume reduction following treatment with sirolimus was higher in fat-poor than fat-rich angiomyolipomas. Tumor reduction was mainly determined by decrease of the fat-poor and highly-vascularized compartments while the volume of the fat-rich compartment increased. Broad liposubstitution was observed in some tumors. A median reduction of 100% (75 to 100) in the diameter of aneurysmatic/ectatic vascular structures was observed. Our study showed that sirolimus reduces the size of angiomyolipomas by decreasing primarily their highly-vascularized and fat-poor compartments. This effect is associated with a remarkable reduction of tumoral aneurysms/ectatic vessels, revealing the likely mechanism responsible for the risk-decreasing effect of mTOR inhibitors on angiomyolipoma bleeding. These findings support the role of mTOR in the development of angiomyolipoma blood vessels.


Assuntos
Angiomiolipoma/tratamento farmacológico , Antibióticos Antineoplásicos/uso terapêutico , Neoplasias Renais/tratamento farmacológico , Lipoma/tratamento farmacológico , Linfangioleiomiomatose/tratamento farmacológico , Sirolimo/uso terapêutico , Esclerose Tuberosa/tratamento farmacológico , Adulto , Angiomiolipoma/patologia , Feminino , Seguimentos , Humanos , Neoplasias Renais/patologia , Lipoma/patologia , Linfangioleiomiomatose/patologia , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos , Esclerose Tuberosa/patologia , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...